270 related articles for article (PubMed ID: 35100482)
1. Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis.
Leonardi L; Adam C; Beaudonnet G; Beauvais D; Cauquil C; Not A; Morassi O; Benmalek A; Trassard O; Echaniz-Laguna A; Adams D; Labeyrie C
Eur J Neurol; 2022 May; 29(5):1477-1487. PubMed ID: 35100482
[TBL] [Abstract][Full Text] [Related]
2. Serum neurofilament light chain levels correlate with small fiber related parameters in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).
Galosi E; Costanzo R; Forcina F; Morino S; Antonini G; Salvetti M; Lauletta A; Luigetti M; Romano A; Primiano G; Guglielmino V; Fionda L; Garibaldi M; Esposito N; Falco P; di Pietro G; Truini A; Leonardi L
Neurol Sci; 2024 May; ():. PubMed ID: 38700599
[TBL] [Abstract][Full Text] [Related]
3. Skin biopsy and quantitative sensory assessment in an Italian cohort of ATTRv patients with polyneuropathy and asymptomatic carriers: possible evidence of early non-length dependent denervation.
Leonardi L; Galosi E; Vanoli F; Fasolino A; Di Pietro G; Luigetti M; Sabatelli M; Fionda L; Garibaldi M; Alfieri G; Lauletta A; Morino S; Salvetti M; Truini A; Antonini G
Neurol Sci; 2022 Feb; 43(2):1359-1364. PubMed ID: 34189665
[TBL] [Abstract][Full Text] [Related]
4. Genetic screening for hereditary transthyretin amyloidosis with polyneuropathy in western Sicily: Two years of experience in a neurological clinic.
Di Stefano V; Lupica A; Alonge P; Pignolo A; Augello SM; Gentile F; Gagliardo A; Giglia F; Brinch D; Cappello M; Di Lisi D; Novo G; Borgione E; Scuderi C; Brighina F
Eur J Neurol; 2024 Jan; 31(1):e16065. PubMed ID: 37725003
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis.
Cárdenas-Soto K; Dominguez XH; Cortes G; Tsai F; Saniger MDM; Guraieb-Chahin P; Torres-Ocatvo B; Gibbons C; Kelly JW; Freeman R; González-Duarte A
J Peripher Nerv Syst; 2024 May; ():. PubMed ID: 38706223
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy.
Ebenezer GJ; Liu Y; Judge DP; Cunningham K; Truelove S; Carter ND; Sebastian B; Byrnes K; Polydefkis M
Ann Neurol; 2017 Jul; 82(1):44-56. PubMed ID: 28598015
[TBL] [Abstract][Full Text] [Related]
7. Corneal confocal microscopy identifies corneal nerve loss and increased Langerhans cells in presymptomatic carriers and patients with hereditary transthyretin amyloidosis.
Thimm A; Carpinteiro A; Oubari S; Papathanasiou M; Kessler L; Rischpler C; Malik RA; Herrmann K; Reinhardt HC; Rassaf T; Kleinschnitz C; Hagenacker T; Stettner M
J Neurol; 2023 Jul; 270(7):3483-3491. PubMed ID: 37014422
[TBL] [Abstract][Full Text] [Related]
8. Correlation between a commercial electrophysiological test of sudomotor function and intraepidermal nerve fiber density in hereditary transthyretin amyloidosis.
Masuda T; Misumi Y; Nomura T; Yamakawa S; Tasaki M; Obayashi K; Ando Y; Ueda M
Muscle Nerve; 2024 Jan; 69(1):99-102. PubMed ID: 37960924
[TBL] [Abstract][Full Text] [Related]
9. Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type.
Papagianni A; Ihne S; Zeller D; Morbach C; Üçeyler N; Sommer C
Amyloid; 2022 Mar; 29(1):14-22. PubMed ID: 34632904
[TBL] [Abstract][Full Text] [Related]
10. Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience.
Ungerer MN; Hund E; Purrucker JC; Huber L; Kimmich C; Aus dem Siepen F; Hein S; Kristen AV; Hinderhofer K; Kollmer J; Schönland S; Hegenbart U; Weiler M
Amyloid; 2021 Jun; 28(2):91-99. PubMed ID: 33283548
[TBL] [Abstract][Full Text] [Related]
11. Quantitative sensory testing and skin biopsy findings in late-onset ATTRv presymptomatic carriers: Relationships with predicted time of disease onset (PADO).
Leonardi L; Costanzo R; Forcina F; Morino S; Antonini G; Salvetti M; Luigetti M; Romano A; Primiano G; Guglielmino V; Fionda L; Garibaldi M; Lauletta A; Rossini E; Tufano L; Ceccanti M; Esposito N; Falco P; di Pietro G; Truini A; Galosi E
J Peripher Nerv Syst; 2023 Sep; 28(3):390-397. PubMed ID: 37535421
[TBL] [Abstract][Full Text] [Related]
12. Red flags and adjusted suspicion index for distinguishing hereditary transthyretin amyloid polyneuropathy from idiopathic axonal polyneuropathy.
Warendorf JK; van der Star GM; Dooijes D; Notermans NC; Vrancken AFJE
Neurol Sci; 2023 Oct; 44(10):3679-3685. PubMed ID: 37266816
[TBL] [Abstract][Full Text] [Related]
13. The neuropathy in hereditary transthyretin amyloidosis: A narrative review.
Tozza S; Severi D; Spina E; Iovino A; Aruta F; Ruggiero L; Dubbioso R; Iodice R; Nolano M; Manganelli F
J Peripher Nerv Syst; 2021 Jun; 26(2):155-159. PubMed ID: 33960565
[TBL] [Abstract][Full Text] [Related]
14. Early changes of nerve integrity in preclinical carriers of hereditary transthyretin Ala117Ser amyloidosis with polyneuropathy.
Chiang MC; Yeh TY; Sung JY; Hsueh HW; Kao YH; Hsueh SJ; Chang KC; Feng FP; Lin YH; Chao CC; Hsieh ST
Eur J Neurol; 2021 Mar; 28(3):982-991. PubMed ID: 33369810
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis.
Berends M; Brunger AF; Bijzet J; Kroesen BJ; Drost G; Lange F; Teunissen CE; In 't Veld S; Vrancken AF; Gans ROB; Hazenberg BPC; van der Zwaag PA; Nienhuis HLA
Amyloid; 2024 Jun; 31(2):132-141. PubMed ID: 38477065
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance neurography and diffusion tensor imaging of the sciatic nerve in hereditary transthyretin amyloidosis polyneuropathy.
Gasparotti R; Salvalaggio A; Corbo D; Agazzi G; Cacciavillani M; Lozza A; Fenu S; De Vigili G; Tagliapietra M; Fabrizi GM; Pareyson D; Obici L; Briani C
J Neurol; 2023 Oct; 270(10):4827-4840. PubMed ID: 37329346
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL
Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140
[TBL] [Abstract][Full Text] [Related]
18. Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis.
Kollmer J; Hegenbart U; Kimmich C; Hund E; Purrucker JC; Hayes JM; Lentz SI; Sam G; Jende JME; Schönland SO; Bendszus M; Heiland S; Weiler M
Ann Clin Transl Neurol; 2020 May; 7(5):799-807. PubMed ID: 32333729
[TBL] [Abstract][Full Text] [Related]
19. Axonal excitability as an early biomarker of nerve involvement in hereditary transthyretin amyloidosis.
Carroll AS; Park SB; Lin CSY; Taylor MS; Kwok F; Simon NG; Reilly MM; Kiernan MC; Vucic S
Clin Neurophysiol; 2024 Mar; 159():81-95. PubMed ID: 38377648
[TBL] [Abstract][Full Text] [Related]
20. Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis.
Lin X; Yarlas A; Vera-Llonch M; Baranwal N; Biber J; Brown D; Vogt B; Karam C
BMC Neurol; 2021 Feb; 21(1):70. PubMed ID: 33579211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
